Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

NCT01810913 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01810913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01810913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Suspended
Start date
March 22, 2013
Completion date
January 1, 2027
Enrollment
613 (estimated)
Sites
342

Conditions

As the registry lists them; a condition with its own page is linked.

oropharyngeal p16ink4a-negative squamous cell carcinoma, stage iii hypopharyngeal squamous cell carcinoma ajcc v7, stage iii laryngeal squamous cell carcinoma ajcc v6 and v7, stage iii oral cavity squamous cell carcinoma ajcc v6 and v7, stage iii oropharyngeal squamous cell carcinoma ajcc v7, stage iv hypopharyngeal squamous cell carcinoma ajcc v7, stage iv laryngeal squamous cell carcinoma ajcc v7, stage iv oral cavity squamous cell carcinoma ajcc v6 and v7, stage iv oropharyngeal squamous cell carcinoma ajcc v7